QCG
KNTE

Quadrant Capital Group’s Kinnate Biopharma Inc. Common Stock KNTE Stock Holding History

Quadrant Capital Group’s Portfolio KNTE Stock Details KNTE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-428
Closed -$5K – 2883
2022
Q3 		$5K Sell
428
-231
-35% -$3.02K ﹤0.01% 2168
2022
Q2 		$8K Sell
659
-357
-35% -$3.32K ﹤0.01% 1806
2022
Q1 		$11K Buy
1,016
+549
+118% +$6.04K ﹤0.01% 1622
2021
Q4 		$8K Buy
467
+445
+2,023% +$9.38K ﹤0.01% 1744
2021
Q3 		$1K Buy
+22
New +$479 ﹤0.01% 2432

Other funds holding KNTE

FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Quadrant Capital Group's KNTE Position: Q4 2022 in Review

Quadrant Capital Group sold out of Kinnate Biopharma Inc. Common Stock (KNTE) in Q4 2022, closing a stake of 428 shares — an estimated $5K sold.

Quadrant Capital Group first reported a position in KNTE in Q3 2021 and held it in 5 quarters. The position peaked at $11K in Q1 2022. 79 funds tracked by Wall St. Rank hold KNTE as of Q4 2022.

  • Quadrant Capital Group reported no remaining Kinnate Biopharma Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Quadrant Capital Group sold 428 Kinnate Biopharma Inc. Common Stock shares in Q4 2022, an estimated $5K.
  • Quadrant Capital Group first reported a position in Kinnate Biopharma Inc. Common Stock in Q3 2021 and held it in 5 quarters.
  • Quadrant Capital Group's Kinnate Biopharma Inc. Common Stock position peaked at $11K in Q1 2022.
  • 79 funds tracked by Wall St. Rank held Kinnate Biopharma Inc. Common Stock as of Q4 2022.

Based on Quadrant Capital Group's 13F filing for Q4 2022, filed 13 Feb 2023.